First Tracks Biotherapeutics, Inc. TRAX
As ofNov 20, 2026, 3:33 PM EST
- YTD
- +120.47%
- 1 year
- +120.47%
- Market cap
- 1.76B
- EPS (ttm)
- -4.71
- Shares out
- 42.02M
- Forward P/E
- -12.84
- YTD return
- +120.47%
- 1-year return
- +120.47%
- 50-day average
- 40.16
- 200-day average
- 31.90
- Enterprise value
- 1.72B
- Volume
- 304.89K
- Avg volume
- 827.06K
- Open
- 43.99
- Previous close
- 44.46
- Day's range
- 41.61 – 44.51
- 52-week range
- 14.72 – 54.78
- Analysts
- Strong Buy
- Price target
- 75.17 (+79.4%)
- Earnings date
- Feb 2, 2027
Key statistics
- Price / book
- 10.57
- Total cash
- 155.63M
- Total debt
- 3.77M
Fundamental scorecard
3 of 25 checks passed on TRAX’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth No data
- Profitability No data
- Financial health 3 of 5
- Dividend No data
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 57.00
- Target (mean)
- 75.17
- Target (high)
- 110.00
- Strong buy3
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 2, 2027
Expected Feb 2, 2027. Consensus EPS estimate -0.7024.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2027 | Dec 30, 2026 | -0.77 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.90274 | -0.88 | +0.02 | +2.52% |
| Aug 12, 2026 | Jun 30, 2026 | -0.80256 | -0.95 | -0.15 | -18.37% |
| May 14, 2026 | Mar 31, 2026 | -0.98059 | -1.45 | -0.47 | -47.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Guggenheim | main | Buy | Buy |
| Oct 16, 2026 | Leerink Partners | main | Outperform | Outperform |
| Oct 13, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 13, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Oct 13, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 30, 2026 | Canaccord Genuity | init | — | Buy |
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- firsttracksbio.com
News
Your note
Sign in to keep a note on TRAX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 19, 2026 | 0 |
| FENTON DENNIS M | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 10,995 |
| JAIN RITA | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 19,194 |
| JOE ANTHONY WARE | Director | Sale | Sep 1, 2026 | 15,660 |
| MARQUET MAGDA | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 15,960 |
| ORWIN JOHN A | Director | Conversion of Exercise of derivative security | Sep 14, 2026 | 17,995 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 7.56% | 3,174,519 | 141.14M | Sep 29, 2026 |
| TCG Crossover Management, LLC | 6.89% | 2,895,304 | 128.73M | Sep 29, 2026 |
| Blackrock Inc. | 6.18% | 2,597,026 | 115.46M | Sep 29, 2026 |
| Affinity Asset Advisors, Llc | 4.95% | 2,080,000 | 92.48M | Sep 29, 2026 |
| Adage Capital Partners GP L.L.C. | 4.94% | 2,077,179 | 92.35M | Sep 29, 2026 |
| FMR, LLC | 4.16% | 1,747,177 | 77.68M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.65% | 1,111,470 | 49.42M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.08% | 874,168 | 38.87M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.06% | 865,021 | 38.46M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.29% | 540,000 | 24.01M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.74% | 309,285 | 13.75M | Jun 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 0.69% | 290,000 | 12.89M | Jul 30, 2026 |
